Cargando…

Evaluation of infliximab/tocilizumab versus tocilizumab among COVID-19 patients with cytokine storm syndrome

Coronavirus Disease 2019 (COVID-19) continues to spread rapidly. Monoclonal antibodies as well as anti-tumor necrosis factor are considered promising treatments for COVID-19. A prospective cohort study in which patients are divided into three groups. Group 1: moderate and severe COVID-19 patients re...

Descripción completa

Detalles Bibliográficos
Autores principales: Sarhan, Neven Mohamed, Warda, Ahmed Essam Abou, Ibrahim, Haytham Soliman Ghareeb, Schaalan, Mona Farag, Fathy, Shaimaa Mohamed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10116445/
https://www.ncbi.nlm.nih.gov/pubmed/37081046
http://dx.doi.org/10.1038/s41598-023-33484-6
_version_ 1785028424605106176
author Sarhan, Neven Mohamed
Warda, Ahmed Essam Abou
Ibrahim, Haytham Soliman Ghareeb
Schaalan, Mona Farag
Fathy, Shaimaa Mohamed
author_facet Sarhan, Neven Mohamed
Warda, Ahmed Essam Abou
Ibrahim, Haytham Soliman Ghareeb
Schaalan, Mona Farag
Fathy, Shaimaa Mohamed
author_sort Sarhan, Neven Mohamed
collection PubMed
description Coronavirus Disease 2019 (COVID-19) continues to spread rapidly. Monoclonal antibodies as well as anti-tumor necrosis factor are considered promising treatments for COVID-19. A prospective cohort study in which patients are divided into three groups. Group 1: moderate and severe COVID-19 patients received standard treatment; Group 2: moderate and severe COVID-19 patients received tocilizumab; Group 3: moderate and severe COVID-19 patients received treatment with infliximab and tocilizumab. 153 patients were recruited in the study. 40 received standard treatment alone, 70 received tocilizumab with standard treatment, and 43 received tocilizumab/infliximab with standard treatment. There was a significant difference in length of hospital stay (10.3, 8.9, and 7.6 days respectively P = 0.03), need for a non-invasive mechanical ventilator (4, 5, and one patient; P = 1.2E−8), intensive care admission (32, 45, and 16 patients; P = 2.5E−5), the occurrence of sepsis (18, 12, and 10 patients; P = 0.005) and in death (42.5%, 14.2%, and 7%; P = 0.0008) which were significantly lower in tocilizumab/infliximab group compared to tocilizumab and standard of care groups. Our study showed that tocilizumab/ infliximab in addition to standard of care was considered a promising treatment for moderate and severe COVID-19 patients. Trial registration number: ClinicalTrials.gov NCT04734678; date of registration: 02/02/2021.
format Online
Article
Text
id pubmed-10116445
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-101164452023-04-22 Evaluation of infliximab/tocilizumab versus tocilizumab among COVID-19 patients with cytokine storm syndrome Sarhan, Neven Mohamed Warda, Ahmed Essam Abou Ibrahim, Haytham Soliman Ghareeb Schaalan, Mona Farag Fathy, Shaimaa Mohamed Sci Rep Article Coronavirus Disease 2019 (COVID-19) continues to spread rapidly. Monoclonal antibodies as well as anti-tumor necrosis factor are considered promising treatments for COVID-19. A prospective cohort study in which patients are divided into three groups. Group 1: moderate and severe COVID-19 patients received standard treatment; Group 2: moderate and severe COVID-19 patients received tocilizumab; Group 3: moderate and severe COVID-19 patients received treatment with infliximab and tocilizumab. 153 patients were recruited in the study. 40 received standard treatment alone, 70 received tocilizumab with standard treatment, and 43 received tocilizumab/infliximab with standard treatment. There was a significant difference in length of hospital stay (10.3, 8.9, and 7.6 days respectively P = 0.03), need for a non-invasive mechanical ventilator (4, 5, and one patient; P = 1.2E−8), intensive care admission (32, 45, and 16 patients; P = 2.5E−5), the occurrence of sepsis (18, 12, and 10 patients; P = 0.005) and in death (42.5%, 14.2%, and 7%; P = 0.0008) which were significantly lower in tocilizumab/infliximab group compared to tocilizumab and standard of care groups. Our study showed that tocilizumab/ infliximab in addition to standard of care was considered a promising treatment for moderate and severe COVID-19 patients. Trial registration number: ClinicalTrials.gov NCT04734678; date of registration: 02/02/2021. Nature Publishing Group UK 2023-04-20 /pmc/articles/PMC10116445/ /pubmed/37081046 http://dx.doi.org/10.1038/s41598-023-33484-6 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Sarhan, Neven Mohamed
Warda, Ahmed Essam Abou
Ibrahim, Haytham Soliman Ghareeb
Schaalan, Mona Farag
Fathy, Shaimaa Mohamed
Evaluation of infliximab/tocilizumab versus tocilizumab among COVID-19 patients with cytokine storm syndrome
title Evaluation of infliximab/tocilizumab versus tocilizumab among COVID-19 patients with cytokine storm syndrome
title_full Evaluation of infliximab/tocilizumab versus tocilizumab among COVID-19 patients with cytokine storm syndrome
title_fullStr Evaluation of infliximab/tocilizumab versus tocilizumab among COVID-19 patients with cytokine storm syndrome
title_full_unstemmed Evaluation of infliximab/tocilizumab versus tocilizumab among COVID-19 patients with cytokine storm syndrome
title_short Evaluation of infliximab/tocilizumab versus tocilizumab among COVID-19 patients with cytokine storm syndrome
title_sort evaluation of infliximab/tocilizumab versus tocilizumab among covid-19 patients with cytokine storm syndrome
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10116445/
https://www.ncbi.nlm.nih.gov/pubmed/37081046
http://dx.doi.org/10.1038/s41598-023-33484-6
work_keys_str_mv AT sarhannevenmohamed evaluationofinfliximabtocilizumabversustocilizumabamongcovid19patientswithcytokinestormsyndrome
AT wardaahmedessamabou evaluationofinfliximabtocilizumabversustocilizumabamongcovid19patientswithcytokinestormsyndrome
AT ibrahimhaythamsolimanghareeb evaluationofinfliximabtocilizumabversustocilizumabamongcovid19patientswithcytokinestormsyndrome
AT schaalanmonafarag evaluationofinfliximabtocilizumabversustocilizumabamongcovid19patientswithcytokinestormsyndrome
AT fathyshaimaamohamed evaluationofinfliximabtocilizumabversustocilizumabamongcovid19patientswithcytokinestormsyndrome